Stock-Based Compensation: The estimated market value of stock options, warrants and other stock-based compensation given to employees and/or vendors.
Verve Therapeutics, Inc. (VERV) had Stock-Based Compensation of $11.17M for the most recently reported fiscal quarter, ending 2025-03-31.
| Income Statement Financials | |
$32.98M |
|
$-31.03M |
|
-- |
|
$32.98M |
|
$69.61M |
|
$-36.64M |
|
$5.68M |
|
$-30.95M |
|
$-30.95M |
|
$-31.03M |
|
$-31.03M |
|
$-31.03M |
|
$-31.03M |
|
$-36.64M |
|
$-36.81M |
|
88.80M |
|
88.80M |
|
$-0.35 |
|
$-0.35 |
|
| Balance Sheet Financials | |
$511.65M |
|
$18.46M |
|
$102.51M |
|
$614.16M |
|
$51.98M |
|
-- |
|
$88.67M |
|
$140.65M |
|
$473.51M |
|
$473.51M |
|
$473.51M |
|
88.80M |
|
| Cash Flow Statement Financials | |
$-27.84M |
|
$-48.17M |
|
$0.01M |
|
$177.33M |
|
$101.33M |
|
$-76.01M |
|
|
Stock-Based Compensation |
$11.17M |
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
9.84 |
|
-- |
|
-- |
|
-- |
|
-- |
|
100.00% |
|
-111.10% |
|
-111.10% |
|
-- |
|
-93.87% |
|
-94.11% |
|
$-29.07M |
|
-- |
|
-- |
|
-- |
|
0.05 |
|
-- |
|
23.57 |
|
3.82 |
|
-6.55% |
|
-6.55% |
|
-5.05% |
|
-6.55% |
|
$5.33 |
|
$-0.33 |
|
$-0.31 |
|